V-Wave to be Acquired by Johnson & Johnson

The producer of interatrial shunts, V-Wave, will be acquired by Johnson & Johnson for a possible sum of up to $1.7 billion. According to the medtech behemoth, the anticipated purchase strengthens its leadership in the field of cardiovascular disease treatment.

V Cardiovascular device technology is developed by V-Wave with a focus on heart failure with a reduced ejection fraction (HFrEF).

Ventura could bridge a therapeutic divide among invasive cardiac replacement treatments, such as left ventricular assist devices (LVADs) and heart transplants, and guideline-directed treatment options as a first-line therapy. Ventura would be inserted into the heart via a minimally invasive, catheter-based method.

Ventura obtained the CE mark in 2020 after first being designated as a breakthrough product by the FDA in 2019. According to J&J, it might be the first product of its sort to be sold. According to the firm, it fills a gap in care for almost 800,000 Americans who suffer with HFrEF each year.